GlaxoSmithKline Pharmaceuticals has decided to discontinue the manufacture and supply of Zinetac tablets (150 mg and 300 mg products) manufactured in India and will in due course request cancellation of the marketing authorization(s) associated with Zinetac Tablets (150mg / 300mg). In the coming months, the company will work closely with the regulatory authorities.
GlaxoSmithKline Pharmaceuticals (GSK Rx India) is one of the oldest pharmaceuticals company. The GSK India product portfolio includes prescription medicines and vaccines.
